After receiving reports from patients who experienced acute renal failure as a result of using the drug, Reclast, the FDA issued an updated warning to healthcare professionals and the general public regarding the risk of kidney failure associated with use of the medication. Levaquin The regulatory agency is requiring that both the drug’s label as well as its medication guide be updated to reflect the risks of severe kidney problems. Additionally, the makers of Reclast have been asked to issue a “Dear Healthcare Provider” informational letter in order to better educate and inform physicians about the risks associated with their product.
The new Reclast label will state that the drug is contraindicated in patients with creatinine clearance less than 35 mL/min or in patients who already exhibit symptoms of acute renal failure. The new label also asks healthcare providers to pre-screen patients prior to using the drug in order to identify those who may already be at increased risk.
